These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

297 related items for PubMed ID: 30075569

  • 1. Clinical characteristics associated with bone mineral density improvement after 1-year alendronate/vitamin d3 or calcitriol treatment: Exploratory results from a phase 3, randomized, controlled trial on postmenopausal osteoporotic women in China.
    Liao EY, Zhang ZL, Xia WB, Lin H, Cheng Q, Wang L, Hao YQ, Chen DC, Tang H, Peng YD, You L, He L, Hu ZH, Song CL, Wei F, Wang J, Zhang L.
    Medicine (Baltimore); 2018 Aug; 97(31):e11694. PubMed ID: 30075569
    [Abstract] [Full Text] [Related]

  • 2. Alendronate sodium/vitamin D3 combination tablet versus calcitriol for osteoporosis in Chinese postmenopausal women: a 6-month, randomized, open-label, active-comparator-controlled study with a 6-month extension.
    Zhang ZL, Liao EY, Xia WB, Lin H, Cheng Q, Wang L, Hao YQ, Chen DC, Tang H, De Peng Y, You L, He L, Hu ZH, Song CL, Wei F, Wang J, Zhang L, Santora AC.
    Osteoporos Int; 2015 Sep; 26(9):2365-74. PubMed ID: 25929192
    [Abstract] [Full Text] [Related]

  • 3. Calcifediol (25-hydroxyvitamin D) improvement and calcium-phosphate metabolism of alendronate sodium/vitamin D3 combination in Chinese women with postmenopausal osteoporosis: a post hoc efficacy analysis and safety reappraisal.
    Liao EY, Zhang ZL, Xia WB, Lin H, Cheng Q, Wang L, Hao YQ, Chen DC, Tang H, Peng YD, You L, He L, Hu ZH, Song CL, Wei F, Wang J, Zhang L.
    BMC Musculoskelet Disord; 2018 Jul 03; 19(1):210. PubMed ID: 29970059
    [Abstract] [Full Text] [Related]

  • 4. Effect of low-dose alendronate treatment on bone mineral density and bone turnover markers in Chinese postmenopausal women with osteopenia and osteoporosis.
    Li M, Zhang ZL, Liao EY, Chen DC, Liu J, Tao TZ, Wu W, Xia WB, Lu YJ, Sheng ZF, Lu CY, Meng GL, Xu L, Zhang WJ, Hu YY, Xu L.
    Menopause; 2013 Jan 03; 20(1):72-8. PubMed ID: 22968256
    [Abstract] [Full Text] [Related]

  • 5. Randomized trial of alendronate plus vitamin D3 versus standard care in osteoporotic postmenopausal women with vitamin D insufficiency.
    Ralston SH, Binkley N, Boonen S, Kiel DP, Reginster JY, Roux C, Chen L, Rosenberg E, Santora A, FOCUS-D (FOSAVANCE vs. Standard Care-Use and Study of Vitamin D) Trial.
    Calcif Tissue Int; 2011 Jun 03; 88(6):485-94. PubMed ID: 21479913
    [Abstract] [Full Text] [Related]

  • 6. Vitamin D status and bone mineral density changes during alendronate treatment in postmenopausal osteoporosis.
    Roux C, Binkley N, Boonen S, Kiel DP, Ralston SH, Reginster JY, Pong A, Rosenberg E, Santora A, FOCUS-D Investigators.
    Calcif Tissue Int; 2014 Feb 03; 94(2):153-7. PubMed ID: 23912950
    [Abstract] [Full Text] [Related]

  • 7. Efficacy of combined treatment with alendronate (ALN) and eldecalcitol, a new active vitamin D analog, compared to that of concomitant ALN, vitamin D plus calcium treatment in Japanese patients with primary osteoporosis.
    Sakai A, Ito M, Tomomitsu T, Tsurukami H, Ikeda S, Fukuda F, Mizunuma H, Inoue T, Saito H, Nakamura T, e-ADVANCED Study Group.
    Osteoporos Int; 2015 Mar 03; 26(3):1193-202. PubMed ID: 25592133
    [Abstract] [Full Text] [Related]

  • 8. Vitamin D, osteoprotegerin/receptor activator of nuclear factor-kappaB ligand (OPG/RANKL) and inflammation with alendronate treatment in HIV-infected patients with reduced bone mineral density.
    Natsag J, Kendall MA, Sellmeyer DE, McComsey GA, Brown TT.
    HIV Med; 2016 Mar 03; 17(3):196-205. PubMed ID: 26177791
    [Abstract] [Full Text] [Related]

  • 9. Concomitant increase in muscle strength and bone mineral density with decreasing IL-6 levels after combination therapy with alendronate and calcitriol in postmenopausal women.
    Park JH, Park KH, Cho S, Choi YS, Seo SK, Lee BS, Park HS.
    Menopause; 2013 Jul 03; 20(7):747-53. PubMed ID: 23511701
    [Abstract] [Full Text] [Related]

  • 10. Effects of discontinuing oral bisphosphonate treatments for postmenopausal osteoporosis on bone turnover markers and bone density.
    Naylor KE, Bradburn M, Paggiosi MA, Gossiel F, Peel NFA, McCloskey EV, Walsh JS, Eastell R.
    Osteoporos Int; 2018 Jun 03; 29(6):1407-1417. PubMed ID: 29525970
    [Abstract] [Full Text] [Related]

  • 11. Alendronate and indapamide alone or in combination in the management of hypercalciuria associated with osteoporosis: a randomized controlled trial of two drugs and three treatments.
    Giusti A, Barone A, Pioli G, Girasole G, Siccardi V, Palummeri E, Bianchi G.
    Nephrol Dial Transplant; 2009 May 03; 24(5):1472-7. PubMed ID: 19075192
    [Abstract] [Full Text] [Related]

  • 12. Secondary hyperparathyroidism due to hypovitaminosis D affects bone mineral density response to alendronate in elderly women with osteoporosis: a randomized controlled trial.
    Barone A, Giusti A, Pioli G, Girasole G, Razzano M, Pizzonia M, Palummeri E, Bianchi G.
    J Am Geriatr Soc; 2007 May 03; 55(5):752-7. PubMed ID: 17493196
    [Abstract] [Full Text] [Related]

  • 13. BMD changes and predictors of increased bone loss in postmenopausal women after a 5-year course of alendronate.
    McNabb BL, Vittinghoff E, Schwartz AV, Eastell R, Bauer DC, Ensrud K, Rosenberg E, Santora A, Barrett-Connor E, Black DM.
    J Bone Miner Res; 2013 Jun 03; 28(6):1319-27. PubMed ID: 23408577
    [Abstract] [Full Text] [Related]

  • 14. Efficacy and tolerability of once-monthly oral ibandronate (150 mg) and once-weekly oral alendronate (70 mg): additional results from the Monthly Oral Therapy With Ibandronate For Osteoporosis Intervention (MOTION) study.
    Emkey R, Delmas PD, Bolognese M, Borges JL, Cosman F, Ragi-Eis S, Recknor C, Zerbini CA, Neate C, Sedarati F, Epstein S.
    Clin Ther; 2009 Apr 03; 31(4):751-61. PubMed ID: 19446148
    [Abstract] [Full Text] [Related]

  • 15. The effect of high-dose vitamin D on bone mineral density and bone turnover markers in postmenopausal women with low bone mass--a randomized controlled 1-year trial.
    Grimnes G, Joakimsen R, Figenschau Y, Torjesen PA, Almås B, Jorde R.
    Osteoporos Int; 2012 Jan 03; 23(1):201-11. PubMed ID: 21909730
    [Abstract] [Full Text] [Related]

  • 16. The use of bone turnover markers for monitoring the treatment of osteoporosis in postmenopausal females undergoing total knee arthroplasty: a prospective randomized study.
    Ma R, Wu M, Li Y, Wang J, Yang P, Chen Y, Wang W, Song J, Wang K.
    J Orthop Surg Res; 2021 Mar 17; 16(1):195. PubMed ID: 33731168
    [Abstract] [Full Text] [Related]

  • 17. Response rate of bone mineral density to teriparatide in postmenopausal women with osteoporosis.
    Gallagher JC, Rosen CJ, Chen P, Misurski DA, Marcus R.
    Bone; 2006 Dec 17; 39(6):1268-75. PubMed ID: 16884968
    [Abstract] [Full Text] [Related]

  • 18. BsmI vitamin D receptor genotypes influence the efficacy of antiresorptive treatments in postmenopausal osteoporotic women. A 1-year multicenter, randomized and controlled trial.
    Palomba S, Orio F, Russo T, Falbo A, Tolino A, Manguso F, Nunziata V, Mastrantonio P, Lombardi G, Zullo F.
    Osteoporos Int; 2005 Aug 17; 16(8):943-52. PubMed ID: 15739035
    [Abstract] [Full Text] [Related]

  • 19. The efficacy and tolerability of once-weekly alendronate 70 mg on bone mineral density and bone turnover markers in postmenopausal Chinese women with osteoporosis.
    Yan Y, Wang W, Zhu H, Li M, Liu J, Luo B, Xie H, Zhang G, Li F.
    J Bone Miner Metab; 2009 Aug 17; 27(4):471-8. PubMed ID: 19343272
    [Abstract] [Full Text] [Related]

  • 20. Effect of intermittent administration of 200 IU intranasal salmon calcitonin and low doses of 1alpha(OH) vitamin D3 on bone mineral density of the lumbar spine and hip region and biochemical bone markers in women with postmenopausal osteoporosis: a pilot study.
    Kaskani E, Lyritis GP, Kosmidis C, Galanos A, Andypas G, Chorianopoulos K, Giagiosis A, Iliadou K, Karagianis A, Katsimichas K, Koskinas A, Matsouka K.
    Clin Rheumatol; 2005 Jun 17; 24(3):232-8. PubMed ID: 15647969
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 15.